GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment. As part of the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discuss ...